PiperJaffray Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $284

PiperJaffray analyst Edward Tenthoff maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $247 to $284.

Benzinga · 01/06/2020 12:56

PiperJaffray analyst Edward Tenthoff maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $247 to $284.